FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB | Market Closed - Bid/Ask 11:53:52 2024-07-10 am EDT | After market 02:03:16 pm | |||
| 41.6 EUR | -22.71% |
|
41.4 | -0.48% |
| Current month | +42.42% | ||
| 1 month | +2.07% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-10 | 41.6 | -22.71% |
| 24-07-09 | 53.82 | -3.77% |
| 24-07-08 | 55.93 | -4.05% |
| 24-07-05 | 58.29 | +10.61% |
| 24-07-04 | 52.7 | -6.74% |
Delayed Quote Börse Stuttgart
Last update July 10, 2024 at 11:53 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SN7D2U |
| ISIN | DE000SN7D2U3 |
| Date issued | 2022-07-28 |
| Strike | 73.58 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 69.09 € |
|---|---|
| Lowest since issue | 1.92 € |
| Spread | 0.46 € |
| Spread % | 1.10% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.86
USD
Average target price
53.1
USD
Spread / Average Target
+29.96%
- Stock Market
- Certificates
- Certificat
